熱門資訊> 正文
ProMIS强调阿尔茨海默氏症和痴呆症出版物将优先靶向可溶性有毒Aβ低聚物与功效和降低ARIA风险联系起来
2025-12-10 20:46
- Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque
- ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer's disease by end of 2025 with planned Q2 2026 interim readout
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。